Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc. (MIST): 2 pipeline candidates · 2 upcoming catalysts · ~34 mo cash runway · 4 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
33.8 months
D/E 4.37 · 0% dilution
Lead: Phase 3
2 candidates
2 upcoming, next in ~1293d
0 buys · 8 sells (180d)
A transparent, data-derived signal for Milestone Pharmaceuticals Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$163.1M
Cash
$71.3M
Quarterly Burn
$16.1M
Runway
33.8 mo
Revenue
$238K
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (2 candidates)
| Drug | Phase |
|---|---|
| cardamyst | Phase 3 |
| etripamil ns | Phase 2 |
Upcoming Catalysts (2)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
82
Total value held
$28.4M
| Holder | Shares | Value |
|---|---|---|
| rtw investments, lp | 6,331,001 | $7.5M |
| two sigma investments, lp | 2,317,176 | $2.8M |
| goldman sachs group inc | 2,000,025 | $2.4M |
| marshall wace, llp | 1,944,530 | $2.3M |
| millennium management llc | 1,544,325 | $1.8M |
| simplify asset management inc. | 1,506,405 | $1.8M |
| balyasny asset management l.p. | 851,325 | $1.0M |
| toronto dominion bank | 750,000 | $893K |
| morgan stanley | 724,141 | $862K |
| boxer capital management, llc | 666,666 | $793K |
Showing top 10 of 82 institutional holders of Milestone Pharmaceuticals Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Milestone Pharmaceuticals Inc.'s pipeline?
Milestone Pharmaceuticals Inc. (MIST) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Milestone Pharmaceuticals Inc.'s lead drug candidate?
Milestone Pharmaceuticals Inc.'s most advanced tracked candidate is cardamyst (Phase 3) for paroxysmal supraventricular tachycardia (PSVT).
What is Milestone Pharmaceuticals Inc.'s next catalyst?
Milestone Pharmaceuticals Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: Multi-Center, Placebo-Controlled, Phase 3 Study of Etripamil Nasal Spray (NS) in Patients With Atria" — expected January 1, 2030.
What is Milestone Pharmaceuticals Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Milestone Pharmaceuticals Inc. has approximately 33.8 months of cash runway.
What is Milestone Pharmaceuticals Inc.'s market capitalization?
Milestone Pharmaceuticals Inc.'s market capitalization is approximately $163.1M.
Get the full picture on Milestone Pharmaceuticals Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.